Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Proactive Technology Helps Keep Chest Tubes Clear

By HospiMedica International staff writers
Posted on 23 Aug 2016
A new system proactively clears chest tubes and prevents the retention of blood and fluids in the chest cavity of cardiothoracic surgery patients.

The PleuraFlow Active Clearance Technology (ACT) system is used to maintain chest tube patency and reduce potential retained blood syndrome (RBS). More...
The system is indicated for use during cardiothoracic surgical procedures and chest trauma. Comprised of a silicone chest tube and a clearance apparatus, the system uses ACT proactively to remove clots formed inside a chest tube to prevent or minimize chest tube occlusion, and to enable evacuation of blood and fluid from the operative site after closure of the surgical wound.

The clearance apparatus consists of a guide tube and a polytetrafluoroethylene (PTFE) -coated clearance wire with a loop set on its distal end, bent at a 105-degree angle. The clearance apparatus is advanced into the PleuraFlow Chest tube using a magnetic shuttle. When indicated, the clearance wire and loop is advanced and retracted within the chest tube to proactively prevent or break up and clear any tube obstructions or clogging, keeping the chest tube patent and allowing fluid flow to the drainage canister.

The PleuraFlow Chest Tube is available in four standard sizes. These include a 20 Fr System with four side holes, intended for infant, preadolescent, and adolescent patients undergoing congenital cardiac surgery; a 20 Fr with 6 side holes for a higher flow rate; and 24 Fr and 38 Fr tubes for larger pediatric patients. Each chest tube has a cut length of 48.3 cm, with graduated measurements in centimeters from the distal eyelet, and a barium stripe to facilitate radiographic visualization. The PleuraFlow System is a product of ClearFlow (Anaheim, CA, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

“We commonly hear from pediatric heart surgeons, pediatric intensive care specialists and ICU nurses that they encounter problems with chest tube clogging after heart surgery in children, and sometimes this results in preventable major complications or even fatal consequences,” said Paul Molloy, CEO of ClearFlow. “The older makeshift bedside techniques of stripping or milking conventional chest tubes have been shown ineffective to prevent these problems, and can even be harmful, and thus are banned in many hospitals.”

RBS is a composite of drainage-related complications that are detrimental to outcomes following cardiothoracic surgery and that may require early or late intervention to remediate. These clinical complications have significant economic consequences, including higher costs of care for patients, hospitals, and society at large.

Related Links:
ClearFlow



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.